Skip to content

Author

Ruijuan Xing

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Jul 2026

Targeting p21-activated kinase 4: Recent advances in the discovery of PAK4 inhibitors and strategies for isoform selectivity.

p21-activated kinase 4 (PAK4), a Group II PAK family member, is a therapeutically relevant candidate target in cancer, metabolic disease, and tissue injury. However, translation of PAK4 biology into drug candidates has been constrained by the conserved ATP-binding architecture of PAK isoforms, unfavorable pharmacokinet...

Rui-Qing Shi, Xue Feng, Zixu Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.